Clinical Trials Logo

Clinical Trial Summary

Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors. The study consisting of two lurbinectedin cycles, one cycle in combination with bosentan and one cycle as single agent (in different order depending on the study sequence), and one additional third cycle of lurbinectedin as a single agent for patients who meet the continuation criteria and obtain a clinical benefit after the first two cycles.


Clinical Trial Description

All patients will receive a maximum of three cycles: two consecutive cycles of lurbinectedin, one cycle with and one cycle without bosentan co-administration (in different order depending on the study Sequence 1 or Sequence 2 of treatment), followed by a third cycle with lurbinectedin alone (this last optional for patients with clinical benefit). Lurbinectedin will be administered as a 1-hour intravenous (i.v.) infusion every three weeks (q3wk) via a central or peripheral vein. The dose of lurbinectedin will be 3.2 mg/m² for all patients when administered with and without bosentan. If toxicity occurs, the appropriate intra-patient dose level (DL) reductions will be implemented in the subsequent cycle. Patients will be randomized in a 1:1 ratio to Sequence 1 (TR: Test-Reference; lurbinectedin + bosentan in Cycle 1) or Sequence 2 (RT: reference-Test; lurbinectedin + bosentan in Cycle 2). Patients will receive lurbinectedin until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest. Treatment with lurbinectedin outside this study could be continued under a Compassionate Use Agreement after the completion of the optional third study cycle. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05072106
Study type Interventional
Source PharmaMar
Contact Pharma Mar, S.A.
Phone +3491 846 6077
Email [email protected]
Status Recruiting
Phase Phase 1
Start date January 14, 2021
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1
Active, not recruiting NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05065710 - A Study of ZL-1211 in Patients With Advanced Solid Tumor Phase 1/Phase 2
Not yet recruiting NCT05001516 - Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04592653 - A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment Phase 2
Active, not recruiting NCT03704246 - Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Phase 2
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Not yet recruiting NCT05036291 - A Study of NB004 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04478461 - Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT04135261 - A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05008445 - Study of LM-102 in Patients With Advance Solid Tumors Phase 1/Phase 2
Completed NCT01387321 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT05021367 - A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT05009966 - Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor Phase 1
Not yet recruiting NCT05051241 - A Study of GFH018 in Patients With Advanced Solid Tumors Phase 1